Fms-Capital District Dialysis Center is a medicare approved dialysis facility center in Schenectady, New York and it has 24 dialysis stations. It is located in Schenectady county at 650 Mcclellan Street, Schenectady, NY, 12304. You can reach out to the office of Fms-Capital District Dialysis Center at (518) 382-0202. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Fms-Capital District Dialysis Center has the following ownership type - Profit. It was first certified by medicare in September, 1988. The medicare id for this facility is 332523 and it accepts patients under medicare ESRD program.
| Name | Fms-Capital District Dialysis Center |
|---|---|
| Location | 650 Mcclellan Street, Schenectady, New York |
| No. of Dialysis Stations | 24 |
| Medicare ID | 332523 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 650 Mcclellan Street, Schenectady, New York, 12304 | |
| (518) 382-0202 | |
News Archive
By using induced pluripotent stem cells to create endothelial cells that line blood vessels in the brain for the first time for a neurodegenerative disease, University of California, Irvine neurobiologists and colleagues have learned why Huntington's disease patients have defects in the blood-brain barrier that contribute to the symptoms of this fatal disorder.
Inovio Pharmaceuticals, Inc., a leader in the development of novel therapeutic and preventive vaccines against cancers and infectious diseases, announced today the presentation of recent preclinical data using its next generation of minimally invasive intradermal (skin) electroporation delivery devices at the Phacilitate Vaccine Forum 2011 in Washington, DC.
Researchers said that developing brain stimulation techniques such as transcranial magnetic stimulation (TMS), vagal nerve stimulation and deep brain stimulation are emerging as significant treatment options for the millions of patients "poorly served" by existing therapies.
Opsens Inc. today released its financial results for the three- and nine-month periods ended May 31, 2010.
AIDS Healthcare Foundation (AHF), today noted that the current "FDA fiasco" involving the agency's initial approval and subsequent recall of Merck's troubled arthritis drug, Vioxx, raises serious questions about the FDA's ongoing parallel role in the approval of generic AIDS drugs for widespread use in Africa and the developing world.
› Verified 6 days ago
| NPI Number | 1326142191 |
| Organization Name | Fms-capital District Dialysis |
| Doing Business As | New York Dialysis Services, Inc. |
| Address | 650 Mcclellan Street Schenectady, New York, 12304 |
| Phone Number | (518) 382-0201 |
News Archive
By using induced pluripotent stem cells to create endothelial cells that line blood vessels in the brain for the first time for a neurodegenerative disease, University of California, Irvine neurobiologists and colleagues have learned why Huntington's disease patients have defects in the blood-brain barrier that contribute to the symptoms of this fatal disorder.
Inovio Pharmaceuticals, Inc., a leader in the development of novel therapeutic and preventive vaccines against cancers and infectious diseases, announced today the presentation of recent preclinical data using its next generation of minimally invasive intradermal (skin) electroporation delivery devices at the Phacilitate Vaccine Forum 2011 in Washington, DC.
Researchers said that developing brain stimulation techniques such as transcranial magnetic stimulation (TMS), vagal nerve stimulation and deep brain stimulation are emerging as significant treatment options for the millions of patients "poorly served" by existing therapies.
Opsens Inc. today released its financial results for the three- and nine-month periods ended May 31, 2010.
AIDS Healthcare Foundation (AHF), today noted that the current "FDA fiasco" involving the agency's initial approval and subsequent recall of Merck's troubled arthritis drug, Vioxx, raises serious questions about the FDA's ongoing parallel role in the approval of generic AIDS drugs for widespread use in Africa and the developing world.
› Verified 6 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 69% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 14% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 17% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 72% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 17% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 11% | 14% |
News Archive
By using induced pluripotent stem cells to create endothelial cells that line blood vessels in the brain for the first time for a neurodegenerative disease, University of California, Irvine neurobiologists and colleagues have learned why Huntington's disease patients have defects in the blood-brain barrier that contribute to the symptoms of this fatal disorder.
Inovio Pharmaceuticals, Inc., a leader in the development of novel therapeutic and preventive vaccines against cancers and infectious diseases, announced today the presentation of recent preclinical data using its next generation of minimally invasive intradermal (skin) electroporation delivery devices at the Phacilitate Vaccine Forum 2011 in Washington, DC.
Researchers said that developing brain stimulation techniques such as transcranial magnetic stimulation (TMS), vagal nerve stimulation and deep brain stimulation are emerging as significant treatment options for the millions of patients "poorly served" by existing therapies.
Opsens Inc. today released its financial results for the three- and nine-month periods ended May 31, 2010.
AIDS Healthcare Foundation (AHF), today noted that the current "FDA fiasco" involving the agency's initial approval and subsequent recall of Merck's troubled arthritis drug, Vioxx, raises serious questions about the FDA's ongoing parallel role in the approval of generic AIDS drugs for widespread use in Africa and the developing world.
› Verified 6 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 59% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 19% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 22% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 58% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 31% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 11% | 12% |
News Archive
By using induced pluripotent stem cells to create endothelial cells that line blood vessels in the brain for the first time for a neurodegenerative disease, University of California, Irvine neurobiologists and colleagues have learned why Huntington's disease patients have defects in the blood-brain barrier that contribute to the symptoms of this fatal disorder.
Inovio Pharmaceuticals, Inc., a leader in the development of novel therapeutic and preventive vaccines against cancers and infectious diseases, announced today the presentation of recent preclinical data using its next generation of minimally invasive intradermal (skin) electroporation delivery devices at the Phacilitate Vaccine Forum 2011 in Washington, DC.
Researchers said that developing brain stimulation techniques such as transcranial magnetic stimulation (TMS), vagal nerve stimulation and deep brain stimulation are emerging as significant treatment options for the millions of patients "poorly served" by existing therapies.
Opsens Inc. today released its financial results for the three- and nine-month periods ended May 31, 2010.
AIDS Healthcare Foundation (AHF), today noted that the current "FDA fiasco" involving the agency's initial approval and subsequent recall of Merck's troubled arthritis drug, Vioxx, raises serious questions about the FDA's ongoing parallel role in the approval of generic AIDS drugs for widespread use in Africa and the developing world.
› Verified 6 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 81% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 19% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 67% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 17% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 16% | 12% |
News Archive
By using induced pluripotent stem cells to create endothelial cells that line blood vessels in the brain for the first time for a neurodegenerative disease, University of California, Irvine neurobiologists and colleagues have learned why Huntington's disease patients have defects in the blood-brain barrier that contribute to the symptoms of this fatal disorder.
Inovio Pharmaceuticals, Inc., a leader in the development of novel therapeutic and preventive vaccines against cancers and infectious diseases, announced today the presentation of recent preclinical data using its next generation of minimally invasive intradermal (skin) electroporation delivery devices at the Phacilitate Vaccine Forum 2011 in Washington, DC.
Researchers said that developing brain stimulation techniques such as transcranial magnetic stimulation (TMS), vagal nerve stimulation and deep brain stimulation are emerging as significant treatment options for the millions of patients "poorly served" by existing therapies.
Opsens Inc. today released its financial results for the three- and nine-month periods ended May 31, 2010.
AIDS Healthcare Foundation (AHF), today noted that the current "FDA fiasco" involving the agency's initial approval and subsequent recall of Merck's troubled arthritis drug, Vioxx, raises serious questions about the FDA's ongoing parallel role in the approval of generic AIDS drugs for widespread use in Africa and the developing world.
› Verified 6 days ago
| Dialysis patients with Hemoglobin data | 69 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 17 |
| Medicare patients who had average hemoglobin (hgb) greater than 12 g/dL | 3 |
News Archive
By using induced pluripotent stem cells to create endothelial cells that line blood vessels in the brain for the first time for a neurodegenerative disease, University of California, Irvine neurobiologists and colleagues have learned why Huntington's disease patients have defects in the blood-brain barrier that contribute to the symptoms of this fatal disorder.
Inovio Pharmaceuticals, Inc., a leader in the development of novel therapeutic and preventive vaccines against cancers and infectious diseases, announced today the presentation of recent preclinical data using its next generation of minimally invasive intradermal (skin) electroporation delivery devices at the Phacilitate Vaccine Forum 2011 in Washington, DC.
Researchers said that developing brain stimulation techniques such as transcranial magnetic stimulation (TMS), vagal nerve stimulation and deep brain stimulation are emerging as significant treatment options for the millions of patients "poorly served" by existing therapies.
Opsens Inc. today released its financial results for the three- and nine-month periods ended May 31, 2010.
AIDS Healthcare Foundation (AHF), today noted that the current "FDA fiasco" involving the agency's initial approval and subsequent recall of Merck's troubled arthritis drug, Vioxx, raises serious questions about the FDA's ongoing parallel role in the approval of generic AIDS drugs for widespread use in Africa and the developing world.
› Verified 6 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 151 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 1304 |
| Percentage of adult patients getting regular hemodialysis at the center | 97 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
By using induced pluripotent stem cells to create endothelial cells that line blood vessels in the brain for the first time for a neurodegenerative disease, University of California, Irvine neurobiologists and colleagues have learned why Huntington's disease patients have defects in the blood-brain barrier that contribute to the symptoms of this fatal disorder.
Inovio Pharmaceuticals, Inc., a leader in the development of novel therapeutic and preventive vaccines against cancers and infectious diseases, announced today the presentation of recent preclinical data using its next generation of minimally invasive intradermal (skin) electroporation delivery devices at the Phacilitate Vaccine Forum 2011 in Washington, DC.
Researchers said that developing brain stimulation techniques such as transcranial magnetic stimulation (TMS), vagal nerve stimulation and deep brain stimulation are emerging as significant treatment options for the millions of patients "poorly served" by existing therapies.
Opsens Inc. today released its financial results for the three- and nine-month periods ended May 31, 2010.
AIDS Healthcare Foundation (AHF), today noted that the current "FDA fiasco" involving the agency's initial approval and subsequent recall of Merck's troubled arthritis drug, Vioxx, raises serious questions about the FDA's ongoing parallel role in the approval of generic AIDS drugs for widespread use in Africa and the developing world.
› Verified 6 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Fms-Capital District Dialysis Center with elevated calcium levels.
| Patients with hypercalcemia | 153 |
| Hypercalcemia patient months | 1329 |
| Patients with Serumphosphor | 158 |
| Patients with Serumphosphor less than 3.5 mg/dL | 8 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 28 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 26 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 23 |
| Patients with Serumphosphor greater than 7 mg/dL | 14 |
News Archive
By using induced pluripotent stem cells to create endothelial cells that line blood vessels in the brain for the first time for a neurodegenerative disease, University of California, Irvine neurobiologists and colleagues have learned why Huntington's disease patients have defects in the blood-brain barrier that contribute to the symptoms of this fatal disorder.
Inovio Pharmaceuticals, Inc., a leader in the development of novel therapeutic and preventive vaccines against cancers and infectious diseases, announced today the presentation of recent preclinical data using its next generation of minimally invasive intradermal (skin) electroporation delivery devices at the Phacilitate Vaccine Forum 2011 in Washington, DC.
Researchers said that developing brain stimulation techniques such as transcranial magnetic stimulation (TMS), vagal nerve stimulation and deep brain stimulation are emerging as significant treatment options for the millions of patients "poorly served" by existing therapies.
Opsens Inc. today released its financial results for the three- and nine-month periods ended May 31, 2010.
AIDS Healthcare Foundation (AHF), today noted that the current "FDA fiasco" involving the agency's initial approval and subsequent recall of Merck's troubled arthritis drug, Vioxx, raises serious questions about the FDA's ongoing parallel role in the approval of generic AIDS drugs for widespread use in Africa and the developing world.
› Verified 6 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 118 |
| Patient months included in arterial venous fistula and catheter summaries | 956 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 54 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 22 |
News Archive
By using induced pluripotent stem cells to create endothelial cells that line blood vessels in the brain for the first time for a neurodegenerative disease, University of California, Irvine neurobiologists and colleagues have learned why Huntington's disease patients have defects in the blood-brain barrier that contribute to the symptoms of this fatal disorder.
Inovio Pharmaceuticals, Inc., a leader in the development of novel therapeutic and preventive vaccines against cancers and infectious diseases, announced today the presentation of recent preclinical data using its next generation of minimally invasive intradermal (skin) electroporation delivery devices at the Phacilitate Vaccine Forum 2011 in Washington, DC.
Researchers said that developing brain stimulation techniques such as transcranial magnetic stimulation (TMS), vagal nerve stimulation and deep brain stimulation are emerging as significant treatment options for the millions of patients "poorly served" by existing therapies.
Opsens Inc. today released its financial results for the three- and nine-month periods ended May 31, 2010.
AIDS Healthcare Foundation (AHF), today noted that the current "FDA fiasco" involving the agency's initial approval and subsequent recall of Merck's troubled arthritis drug, Vioxx, raises serious questions about the FDA's ongoing parallel role in the approval of generic AIDS drugs for widespread use in Africa and the developing world.
› Verified 6 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 155 |
| Hospitalization Rate in facility | 234.9 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 345.6 |
| Hospitalization Rate: Lower Confidence Limit | 169.3 |
News Archive
By using induced pluripotent stem cells to create endothelial cells that line blood vessels in the brain for the first time for a neurodegenerative disease, University of California, Irvine neurobiologists and colleagues have learned why Huntington's disease patients have defects in the blood-brain barrier that contribute to the symptoms of this fatal disorder.
Inovio Pharmaceuticals, Inc., a leader in the development of novel therapeutic and preventive vaccines against cancers and infectious diseases, announced today the presentation of recent preclinical data using its next generation of minimally invasive intradermal (skin) electroporation delivery devices at the Phacilitate Vaccine Forum 2011 in Washington, DC.
Researchers said that developing brain stimulation techniques such as transcranial magnetic stimulation (TMS), vagal nerve stimulation and deep brain stimulation are emerging as significant treatment options for the millions of patients "poorly served" by existing therapies.
Opsens Inc. today released its financial results for the three- and nine-month periods ended May 31, 2010.
AIDS Healthcare Foundation (AHF), today noted that the current "FDA fiasco" involving the agency's initial approval and subsequent recall of Merck's troubled arthritis drug, Vioxx, raises serious questions about the FDA's ongoing parallel role in the approval of generic AIDS drugs for widespread use in Africa and the developing world.
› Verified 6 days ago
The rate of readmission show you whether patients who were being treated regularly at Fms-Capital District Dialysis Center were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 24.1 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 29.9 |
| Readmission Rate: Lower Confidence Limit | 18.9 |
News Archive
By using induced pluripotent stem cells to create endothelial cells that line blood vessels in the brain for the first time for a neurodegenerative disease, University of California, Irvine neurobiologists and colleagues have learned why Huntington's disease patients have defects in the blood-brain barrier that contribute to the symptoms of this fatal disorder.
Inovio Pharmaceuticals, Inc., a leader in the development of novel therapeutic and preventive vaccines against cancers and infectious diseases, announced today the presentation of recent preclinical data using its next generation of minimally invasive intradermal (skin) electroporation delivery devices at the Phacilitate Vaccine Forum 2011 in Washington, DC.
Researchers said that developing brain stimulation techniques such as transcranial magnetic stimulation (TMS), vagal nerve stimulation and deep brain stimulation are emerging as significant treatment options for the millions of patients "poorly served" by existing therapies.
Opsens Inc. today released its financial results for the three- and nine-month periods ended May 31, 2010.
AIDS Healthcare Foundation (AHF), today noted that the current "FDA fiasco" involving the agency's initial approval and subsequent recall of Merck's troubled arthritis drug, Vioxx, raises serious questions about the FDA's ongoing parallel role in the approval of generic AIDS drugs for widespread use in Africa and the developing world.
› Verified 6 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Fms-Capital District Dialysis Center get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .57 (As Expected) |
| SIR: Upper Confidence Limit | 1.12 |
| SIR: Lower Confidence Limit | .25 |
News Archive
By using induced pluripotent stem cells to create endothelial cells that line blood vessels in the brain for the first time for a neurodegenerative disease, University of California, Irvine neurobiologists and colleagues have learned why Huntington's disease patients have defects in the blood-brain barrier that contribute to the symptoms of this fatal disorder.
Inovio Pharmaceuticals, Inc., a leader in the development of novel therapeutic and preventive vaccines against cancers and infectious diseases, announced today the presentation of recent preclinical data using its next generation of minimally invasive intradermal (skin) electroporation delivery devices at the Phacilitate Vaccine Forum 2011 in Washington, DC.
Researchers said that developing brain stimulation techniques such as transcranial magnetic stimulation (TMS), vagal nerve stimulation and deep brain stimulation are emerging as significant treatment options for the millions of patients "poorly served" by existing therapies.
Opsens Inc. today released its financial results for the three- and nine-month periods ended May 31, 2010.
AIDS Healthcare Foundation (AHF), today noted that the current "FDA fiasco" involving the agency's initial approval and subsequent recall of Merck's troubled arthritis drug, Vioxx, raises serious questions about the FDA's ongoing parallel role in the approval of generic AIDS drugs for widespread use in Africa and the developing world.
› Verified 6 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Fms-Capital District Dialysis Center's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 124 |
| Transfusion Rate in facility | 38.5 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 79.1 |
| Transfusion Rate: Lower Confidence Limit | 20.4 |
News Archive
By using induced pluripotent stem cells to create endothelial cells that line blood vessels in the brain for the first time for a neurodegenerative disease, University of California, Irvine neurobiologists and colleagues have learned why Huntington's disease patients have defects in the blood-brain barrier that contribute to the symptoms of this fatal disorder.
Inovio Pharmaceuticals, Inc., a leader in the development of novel therapeutic and preventive vaccines against cancers and infectious diseases, announced today the presentation of recent preclinical data using its next generation of minimally invasive intradermal (skin) electroporation delivery devices at the Phacilitate Vaccine Forum 2011 in Washington, DC.
Researchers said that developing brain stimulation techniques such as transcranial magnetic stimulation (TMS), vagal nerve stimulation and deep brain stimulation are emerging as significant treatment options for the millions of patients "poorly served" by existing therapies.
Opsens Inc. today released its financial results for the three- and nine-month periods ended May 31, 2010.
AIDS Healthcare Foundation (AHF), today noted that the current "FDA fiasco" involving the agency's initial approval and subsequent recall of Merck's troubled arthritis drug, Vioxx, raises serious questions about the FDA's ongoing parallel role in the approval of generic AIDS drugs for widespread use in Africa and the developing world.
› Verified 6 days ago
The rate of mortality show you whether patients who were being treated regularly at Fms-Capital District Dialysis Center lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 801 |
| Mortality Rate in facility | 21.3 (Worse than Expected) |
| Mortality Rate: Upper Confidence Limit | 25.6 |
| Mortality Rate: Lower Confidence Limit | 17.6 |
News Archive
By using induced pluripotent stem cells to create endothelial cells that line blood vessels in the brain for the first time for a neurodegenerative disease, University of California, Irvine neurobiologists and colleagues have learned why Huntington's disease patients have defects in the blood-brain barrier that contribute to the symptoms of this fatal disorder.
Inovio Pharmaceuticals, Inc., a leader in the development of novel therapeutic and preventive vaccines against cancers and infectious diseases, announced today the presentation of recent preclinical data using its next generation of minimally invasive intradermal (skin) electroporation delivery devices at the Phacilitate Vaccine Forum 2011 in Washington, DC.
Researchers said that developing brain stimulation techniques such as transcranial magnetic stimulation (TMS), vagal nerve stimulation and deep brain stimulation are emerging as significant treatment options for the millions of patients "poorly served" by existing therapies.
Opsens Inc. today released its financial results for the three- and nine-month periods ended May 31, 2010.
AIDS Healthcare Foundation (AHF), today noted that the current "FDA fiasco" involving the agency's initial approval and subsequent recall of Merck's troubled arthritis drug, Vioxx, raises serious questions about the FDA's ongoing parallel role in the approval of generic AIDS drugs for widespread use in Africa and the developing world.
› Verified 6 days ago
Fms-Capital District Dialysis Center Location: 650 Mcclellan Street, Schenectady, New York, 12304 Phone: (518) 382-0202 |
Fms-Niskayuna Dialysis Center Location: 2345 Nott Street East, Schenectady, New York, 12309 Phone: (518) 346-5186 |
Schenectady Partners Llc Location: 1594 State Street, Schenectady, New York, 12304 Phone: (518) 382-5309 |
News Archive
By using induced pluripotent stem cells to create endothelial cells that line blood vessels in the brain for the first time for a neurodegenerative disease, University of California, Irvine neurobiologists and colleagues have learned why Huntington's disease patients have defects in the blood-brain barrier that contribute to the symptoms of this fatal disorder.
Inovio Pharmaceuticals, Inc., a leader in the development of novel therapeutic and preventive vaccines against cancers and infectious diseases, announced today the presentation of recent preclinical data using its next generation of minimally invasive intradermal (skin) electroporation delivery devices at the Phacilitate Vaccine Forum 2011 in Washington, DC.
Researchers said that developing brain stimulation techniques such as transcranial magnetic stimulation (TMS), vagal nerve stimulation and deep brain stimulation are emerging as significant treatment options for the millions of patients "poorly served" by existing therapies.
Opsens Inc. today released its financial results for the three- and nine-month periods ended May 31, 2010.
AIDS Healthcare Foundation (AHF), today noted that the current "FDA fiasco" involving the agency's initial approval and subsequent recall of Merck's troubled arthritis drug, Vioxx, raises serious questions about the FDA's ongoing parallel role in the approval of generic AIDS drugs for widespread use in Africa and the developing world.
› Verified 6 days ago